Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017–2018 and 2018–2019 Influenza Seasons
| Autor: | Constantina Boikos, Lauren Fischer, James A. Mansi, Gregg C Sylvester, Daniel P O'Brien, Joseph Vasey |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Microbiology (medical) Quadrivalent Inactivated Influenza Vaccine Trivalent influenza vaccine medicine.medical_specialty influenza-related medical encounters Influenza vaccine relative effectiveness 03 medical and health sciences 0302 clinical medicine Internal medicine Influenza Human medicine Humans 030212 general & internal medicine older adults Aged Retrospective Studies business.industry Medical record Retrospective cohort study adjuvanted trivalent inactivated influenza vaccine Odds ratio Confidence interval United States Vaccination Major Articles and Commentaries 030104 developmental biology Infectious Diseases AcademicSubjects/MED00290 Vaccines Inactivated Influenza Vaccines Seasons business influenza |
| Zdroj: | Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America |
| ISSN: | 1537-6591 1058-4838 |
| Popis: | Background The effectiveness of standard, egg-derived quadrivalent influenza vaccines (IIV4) may be reduced in adults ≥65 years of age, largely because of immunosenescence. An MF59-adjuvanted trivalent influenza vaccine (aIIV3) and a high-dose trivalent influenza vaccine (HD-IIV3) offer older adults enhanced protection versus standard vaccines. This study compared the relative effectiveness of aIIV3 with IIV4 and HD-IIV3 in preventing influenza-related medical encounters over 2 US influenza seasons. Methods This retrospective cohort study included US patients ≥65 years vaccinated with aIIV3, IIV4, or HD-IIV3. The outcome of interest was the occurrence of influenza-related medical encounters. Data were derived from a large dataset comprising primary and specialty care electronic medical records linked with pharmacy and medical claims. Adjusted odds ratios (OR) were derived from an inverse probability of treatment-weighted sample adjusted for age, sex, race, ethnicity, geographic region, vaccination week, and health status. Relative vaccine effectiveness (rVE) was determined using the formula (% VE = 1 – ORadjusted) × 100. Results In 2017–2018, cohorts included: aIIV3, n = 524 223; IIV4, n = 917 609; and HD-IIV3, n = 3 377 860. After adjustment, 2017–2018 rVE of aIIV3 versus IIV4 was 18.2 (95% confidence interval [CI], 15.8–20.5); aIIV3 vs. HD-IIV3 was 7.7 (95% CI, 2.3–12.8). In 2018–2019, cohorts included: aIIV3, n = 1 031 145; IIV4, n = 915 380; HD-IIV3, n = 3 809 601, with adjusted rVEs of aIIV3 versus IIV4 of 27.8 (95% CI, 25.7–29.9) and vs. HD-IIV3 of 6.9 (95% CI, 3.1–10.6). Conclusion In the 2017–2018 and 2018–2019 influenza seasons in the United States, aIIV3 demonstrated greater reduction in influenza-related medical encounters than IIV4 and HD-IIV3 in adults ≥65 years. During the 2017–2018 and 2018–2019 US influenza seasons, the adjuvanted trivalent inactivated influenza vaccine (aIIV3) demonstrated statistically significantly greater effectiveness in reducing influenza-related medical encounters versus standard, egg-derived quadrivalent influenza vaccines (IIV4) and the high-dose trivalent inactivated influenza vaccine (HD-IIV3). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|